ONWARD MEDICAL news, videos and press releases - Page 2
For more news please use our advanced search feature.
ONWARD MEDICAL - More news...
ONWARD MEDICAL - More news...
- ONWARD® Medical to Host Webcast to Share Details from its Up-LIFT Trial and Yesterday’s Nature Medicine Publication
- Nature Medicine Highlights Significant Improvement in Hand and Arm Function After Spinal Cord Injury with Use of ONWARD® ARC-EX® Therapy
- ONWARD® Medical Schedules Webcast to Provide Q1 2024 Business Update
- ONWARD® Medical Convocation of the 2024 Annual General Meeting of Shareholders and Proposed Resolutions
- ONWARD® Medical Reports Full Year 2023 Financial and Operating Results and Shares 2024 Highlights Year-to-Date
- ONWARD® Medical Announces Publication of Full Year 2023 Financial Results and Business Update Webcast
- Stifel Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 12.00
- ONWARD® Medical Submits De Novo Application to FDA for its ARC-EX® System
- ONWARD® Medical Publishes Closing of Accelerated Bookbuild Offering and Public Offering in France
- ONWARD® Medical Publishes Prospectus for Listing of New Shares
- ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option
- ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option
- ONWARD® Medical Successfully Completes Benchmark Testing on Path to Commercialize ARC-EX® System
- ONWARD® Medical Reaffirms Guidance, Shares 2024 Strategic Priorities, and Releases Unaudited Q4 Financial Highlights
- ONWARD® Medical Accepted to New US FDA TAP Program for Development of its ARC-BCI™ System
- ONWARD® Medical Awarded 10th Breakthrough Device Designation for Brain-Computer Interface (BCI) from US FDA
- KBC Securities Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 10.00 Per Share
- ONWARD® MEDICAL ANNOUNCES PRESENTATION AT BIOCAPITAL EUROPE
- ONWARD® ARC Therapy™ Highlighted at 2024 Annual Meeting of the North American Neuromodulation Society (NANS)
- ONWARD® to Participate in Basel Healthtech Conference 2024
- ONWARD® to Participate in Degroof Petercam Healthcare Conference
- ONWARD® Announces Start of HemON NL Clinical Study
- ONWARD Schedules Webcast to Provide Third Quarter 2023 Business Update
- ONWARD® Reports 2023 Half Year Results and Business Update
- ONWARD® Launches Partnership with Service-Disabled Veteran-Owned Business to Access U.S. Federal Health Market
- ONWARD Announces Results of Annual General Meeting of Shareholders
- ONWARD Schedules Webcast to Provide First Quarter Business Update
- ONWARD to Attend Upcoming Scientific and Investor Events
- ONWARD Does Not Hold Cash Deposits at Silicon Valley Bank
- ONWARD Reports Interim Clinical Outcomes for Implantable ARC Therapy Demonstrating Potential to Improve Blood Pressure Regulation after Spinal Cord Injury
